research use only
Cat.No.S9827
|
In vitro |
DMSO
: 40 mg/mL
(216.26 mM)
Water : 40 mg/mL Ethanol : 40 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 184.96 | Formula | C2H4INO |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 144-48-9 | -- | Storage of Stock Solutions |
|
|
| In vitro |
A multiple cleavage cascade mechanism is partially utilized to produce virus structural proteins. In infected cells, the largest viral induced protein obtained has a molecular weight of 144,000. Pretreatment of the infected cells with iodoacetamide before pulsing with 35S-methionine results in the appearance of two polypeptides of molecular weights 205,000 and 190,000. Other changes occur in viral protein precursors in the presence of this compound. |
|---|---|
| In vivo |
Iodoacetamide induces a concentration-dependent weight loss and reduces water intake in both species (Wistar rats and CD1, C57Bl/6J mice). This compound induces gastritis in rats. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05986214 | Not yet recruiting | Chronic Obstructive Pulmonary Disease |
VA Office of Research and Development |
March 1 2026 | Not Applicable |
| NCT06376253 | Not yet recruiting | Ovarian Cancer|Lung Cancer |
Novartis Pharmaceuticals|Novartis |
September 6 2024 | Phase 1 |
| NCT06406309 | Not yet recruiting | Attention Deficit Hyperactivity Disorder|Sleep Disturbance |
University of Pittsburgh|The Klingenstein Third Generation Foundation |
September 2024 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.